Merck Can't Force Fosamax Plaintiffs To Verify Injuries

Law360, New York (August 22, 2013, 7:31 PM EDT) -- A New York federal judge on Thursday refused to force hundreds of alleged victims of Merck & Co.’s bone drug Fosamax to substantiate their injuries or else face dismissal from multidistrict litigation over the drug, saying the process would devolve into a fight on the merits of each case.

Lawyers for Merck said at a hearing last week that they had identified nearly 600 questionable cases in the multidistrict litigation, and asked U.S. District Judge John Keenan to issue a so-called Lone Pine order requiring those...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.